cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25505/fiz.icsd.cc21cgqm
title: CSD 1887860: Experimental Crystal Structure Determination

description: Related Article: Zhiying Zhao|2018|ICSD Communication|||
description: Related Article: Zhiying Zhao, Wanwan Zhang, Zhangzhen He|2019|Inorg.Chem.|58|5671|doi:10.1021/acs.inorgchem.9b00008
DOI: 10.5517/ccdc.csd.cc21bzky
title: CCDC 1887390: Experimental Crystal Structure Determination

description: Related Article: Narumasa Saito, Jun Takaya, Nobuharu Iwasawa|2019|Angew.Chem.,Int.Ed.|58|9998|doi:10.1002/anie.201904968
description: Related Article: Tuhin Ganguly, Ayan Das, Amit Majumdar|2019|Inorg.Chem.|58|9998|doi:10.1021/acs.inorgchem.9b01144
DOI: 10.5517/ccdc.csd.cc21d07q
title: CCDC 1888372: Experimental Crystal Structure Determination

description: Related Article: S. Pangajavalli, R. Ranjithkumar, N. Srinivasan, S. Ramaswamy, S. Selvanayagam|2019|Acta Crystallogr.,Sect.E:Cryst.Commun.|75|246|doi:10.1107/S2056989019000045
DOI: 10.5517/ccdc.csd.cc21d08r
title: CCDC 1888373: Experimental Crystal Structure Determination

description: Related Article: S. Pangajavalli, R. Ranjithkumar, N. Srinivasan, S. Ramaswamy, S. Selvanayagam|2019|Acta Crystallogr.,Sect.E:Cryst.Commun.|75|246|doi:10.1107/S2056989019000045
DOI: 10.25505/fiz.icsd.cc21d42p
title: CSD 1888491: Experimental Crystal Structure Determination

description: Related Article: Jiaxu Zhang, Xiaoshuang Liu, Yayun Ding, Chaozhuang Xue, Tao Wu|2019|Dalton Trans.|48|7537|doi:10.1039/C9DT01410A
DOI: 10.25505/fiz.icsd.cc1zzxxs
title: CSD 1846977: Experimental Crystal Structure Determination

description: Related Article: F. Giovannelli, C. Mathieu, K. Fritsch, K. Adil, F. Goutenoire, K. Habicht, F. Delorme|2019|Acta Crystallogr.,Sect.B:Struct.Sci.,Cryst.Eng. and Mat.|75|127|doi:10.1107/S2052520619000064
DOI: 10.25505/fiz.icsd.cc21d69z
title: CSD 1888560: Experimental Crystal Structure Determination

description: Related Article: Steffen Klenner, Lukas Heletta, Rainer Pöttgen|2019|Dalton Trans.|48|3648|doi:10.1039/C9DT00035F
DOI: 10.25505/fiz.icsd.cc21d6b0
title: CSD 1888561: Experimental Crystal Structure Determination

description: Related Article: Steffen Klenner, Lukas Heletta, Rainer Pöttgen|2019|Dalton Trans.|48|3648|doi:10.1039/C9DT00035F
DOI: 10.25505/fiz.icsd.cc21d6c1
title: CSD 1888562: Experimental Crystal Structure Determination

description: Related Article: Steffen Klenner, Lukas Heletta, Rainer Pöttgen|2019|Dalton Trans.|48|3648|doi:10.1039/C9DT00035F
DOI: 10.25505/fiz.icsd.cc21dhzy
title: CSD 1888860: Experimental Crystal Structure Determination

description: Related Article: Liurukara D. Sanjeewa, Kyle Fulle, Colin D. McMillen, Joseph W. Kolis|2019|Dalton Trans.|48|7704|doi:10.1039/C9DT00059C
DOI: 10.25505/fiz.icsd.cc21dj00
title: CSD 1888861: Experimental Crystal Structure Determination

description: Related Article: Liurukara D. Sanjeewa, Kyle Fulle, Colin D. McMillen, Joseph W. Kolis|2019|Dalton Trans.|48|7704|doi:10.1039/C9DT00059C
DOI: 10.25505/fiz.icsd.cc21dj11
title: CSD 1888862: Experimental Crystal Structure Determination

description: Related Article: Liurukara D. Sanjeewa, Kyle Fulle, Colin D. McMillen, Joseph W. Kolis|2019|Dalton Trans.|48|7704|doi:10.1039/C9DT00059C
DOI: 10.25505/fiz.icsd.cc21dj22
title: CSD 1888863: Experimental Crystal Structure Determination

description: Related Article: Liurukara D. Sanjeewa, Kyle Fulle, Colin D. McMillen, Joseph W. Kolis|2019|Dalton Trans.|48|7704|doi:10.1039/C9DT00059C
DOI: 10.25505/fiz.icsd.cc21dj33
title: CSD 1888864: Experimental Crystal Structure Determination

description: Related Article: Liurukara D. Sanjeewa, Kyle Fulle, Colin D. McMillen, Joseph W. Kolis|2019|Dalton Trans.|48|7704|doi:10.1039/C9DT00059C
DOI: 10.25505/fiz.icsd.cc21dqy4
title: CSD 1889076: Experimental Crystal Structure Determination

description: Related Article: Sung-Ji Lim, Gnu Nam, Seungeun Shin, Kyunghan Ahn, Yunho Lee, Tae-Soo You|2019|Inorg.Chem.|58|5827|doi:10.1021/acs.inorgchem.9b00181
DOI: 10.25505/fiz.icsd.cc21dqz5
title: CSD 1889077: Experimental Crystal Structure Determination

description: Related Article: Sung-Ji Lim, Gnu Nam, Seungeun Shin, Kyunghan Ahn, Yunho Lee, Tae-Soo You|2019|Inorg.Chem.|58|5827|doi:10.1021/acs.inorgchem.9b00181
DOI: 10.25505/fiz.icsd.cc21dxt6
title: CSD 1889258: Experimental Crystal Structure Determination

description: Related Article: N. Pavlyuk, G. Dmytriv, V. Pavlyuk, H. Ehrenberg|2019|Acta Crystallogr.,Sect.B:Struct.Sci.,Cryst.Eng. and Mat.|75|168|doi:10.1107/S2052520619000349
DOI: 10.25505/fiz.icsd.cc21256j
title: CSD 1878916: Experimental Crystal Structure Determination

description: Related Article: Jianjun Tian, Valentin N. Ivanovski, David Szalda, Hechang Lei, Aifeng Wang, Yu Liu, Weifeng Zhang, Vasil Koteski, Cedomir Petrovic|2019|Inorg.Chem.|58|3107|doi:10.1021/acs.inorgchem.8b03089
DOI: 10.5517/ccdc.csd.cc21fb3y
title: CCDC 1889639: Experimental Crystal Structure Determination

description: Related Article: Dao-Juan Cheng, Rui-Qi Li, Xing-Shuai Zhang, Lin Zhao, Tao Wang, You-Dong Shao|2019|Eur.J.Org.Chem.|2019|496|doi:10.1002/ejoc.201901774
DOI: 10.25934/pr00002453.0
title: Available IPD datapackage for study 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus'

description: The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus
DOI: 10.25934/pr00002449.0
title: Available IPD datapackage for study 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes'

description: The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.
DOI: 10.5281/zenodo.5838657
title: Screening of ~7000 coronavirus-specific compounds for anti-SARS-CoV-2 activity

description: This short report describes the most relevant results of screening selected compounds with potential activity against SARS-CoV-2 in a VeroE6 cell-based anti-SARS-CoV-2 assay.
DOI: 10.5281/zenodo.5838656
title: Screening of ~7000 coronavirus-specific compounds for anti-SARS-CoV-2 activity

description: This short report describes the most relevant results of screening selected compounds with potential activity against SARS-CoV-2 in a VeroE6 cell-based anti-SARS-CoV-2 assay.
DOI: 10.25934/pr00002454.0
title: Available IPD datapackage for study 'A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes'

description: The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
DOI: 10.5281/zenodo.5758163
title: Los Alamos National Laboratory (LANL) Geosynchronous Particle Data for Di Matteo, S., et al., (2022)

description: This repository holds data from a set of charged particle analyzers developed and operated by Los Alamos National Laboratory (LANL). The detectors have been hosted on a variety of satellites at geosynchronous orbit. The data are used in the following open access publication submitted to the Journal of Geophysical Research, Space Physics. Di Matteo, S., Villante, U., Viall, N. M., Kepko, L., & Wallace, S. (2021). On differentiating multiple types of ULF magnetospheric waves in response to solar wind periodic density structures. Earth and Space Science Open Archive, 59. Retrieved from https://doi.org/10.1002/essoar.10508935.1
DOI: 10.5281/zenodo.5758162
title: Los Alamos National Laboratory (LANL) Geosynchronous Particle Data for Di Matteo, S., et al., (2022)

description: This repository holds data from a set of charged particle analyzers developed and operated by Los Alamos National Laboratory (LANL). The detectors have been hosted on a variety of satellites at geosynchronous orbit. The data are used in the following open access publication submitted to the Journal of Geophysical Research, Space Physics. Di Matteo, S., Villante, U., Viall, N. M., Kepko, L., & Wallace, S. (2021). On differentiating multiple types of ULF magnetospheric waves in response to solar wind periodic density structures. Earth and Space Science Open Archive, 59. Retrieved from https://doi.org/10.1002/essoar.10508935.1
DOI: 10.25919/6p37-pe07
title: Parkes observations for project PX500 semester 2021OCTS_21

description: This proposal relates to time purchased by the Chinese Academy of Sciences for Parkes follow-up confirmation and timing of FAST discoveries. As the observing time has been purchased this proposal (and the related PX501) does not require TAC grading. The primary reason for submitting a proposal is to ensure an outreach statement and that the proposal is entered into OPAL for the data archive to access. The Chinese team have two time requests. The time scheduled for the first, relating to this proposal, will be allocated in blocks of 24 hours and the data will become available in the data archive with an 18 month embargo period. The second type of time will be scheduled in shorter blocks and the data archived with a 10 year embargo.
DOI: 10.5281/zenodo.5838675
title: Screening of 67 compounds with predicted biosignature profile similar to remdesivir for anti-SARS-CoV-2 activity

description: This short report describes the most relevant results of screening compounds with a similar predicted biosignature as remdesivir in a VeroE6 cell-based anti-SARS-CoV-2 assay.
DOI: 10.5281/zenodo.5838674
title: Screening of 67 compounds with predicted biosignature profile similar to remdesivir for anti-SARS-CoV-2 activity

description: This short report describes the most relevant results of screening compounds with a similar predicted biosignature as remdesivir in a VeroE6 cell-based anti-SARS-CoV-2 assay.
DOI: 10.21410/dshs_2016/qwdfmd
title: Quand des Français, des Anglais et des Belges (francophones) parlent d'Europe [2005-2006]

description: Cette enquête porte sur la politisation et la polarisation des réactions à l’égard de l’intégration européenne. Elle vise notamment à comprendre comment les conversations deviennent politiques, et en comparant pour ce faire la manière dont les Français, les Belges francophones et les Britanniques discutent de l’Europe.
DOI: 10.5281/zenodo.5838684
title: Screening of 452 hit enrichment compounds for anti-SARS-CoV-2 activity meta data

description: This short report describes the most relevant results of screening selected compounds from the Janssen Pharmaceutica compound collection in a VeroE6 cell-based anti-SARS-CoV-2 assay.
DOI: 10.5281/zenodo.5838683
title: Screening of 452 hit enrichment compounds for anti-SARS-CoV-2 activity meta data

description: This short report describes the most relevant results of screening selected compounds from the Janssen Pharmaceutica compound collection in a VeroE6 cell-based anti-SARS-CoV-2 assay.
DOI: 10.25345/c5cw0w
title: MassIVE MSV000088673 - Cyrtopodium glutiniferum Raddi_Atlantic Forest
title: Extracts of orchids have been traditionally used as human phytotherapeutics. Cyrtopodium glutiniferum, an orchid found in the Brazilian southeastern rainforest, is known to synthesize anti-inflammatory and other potentially therapeutic compounds.
DOI: 10.5281/zenodo.5838709
title: IDSL.UFA Annotation for Selected Metabolomics Studies

description: Formula annotations for ST001154, ST001683, MTBLS1684, and MTBLS2542 studies were summarized.
DOI: 10.5281/zenodo.5838708
title: IDSL.UFA Annotation for Selected Metabolomics Studies

description: Formula annotations for ST001154, ST001683, MTBLS1684, and MTBLS2542 studies were summarized.
DOI: 10.25934/pr00002532.0
title: Available IPD datapackage for study 'A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan'

description: The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.
DOI: 10.25934/pr00002533.0
title: Available IPD datapackage for study 'A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Sulfonylurea in Subjects With Type 2 Diabetes in Japan'

description: The purpose of this study was evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an Sulfonylurea taken QD or twice daily (BID) in type 2 diabetic patients with uncontrolled blood glucose.
DOI: 10.6084/m9.figshare.18183440
title: Supplemental Table 4

description: Test information of GLM LASSO runs where growth data from each plant was scrambled across different rhizosphere samples to evaluate false positive detection rates. Number of features detected from scrambled data at each step are shown. Gray rows indicate tests with false positive detection rates above 1%, where any features found in unscrambled data were omitted. <br>
DOI: 10.6084/m9.figshare.18183356
title: Supplemental Table 3

description: Summary table of best Bayesian multivariate models for all test combinations of features, sample groups, and plant growth response data. Marginal and conditional R\textsuperscript{2} values are shown for each model. For ASV models, prevalence thresholds for GLM LASSO runs are specified. Pairs of rows shaded in gray represent equally good models derived from GLM LASSO runs at different prevalence thresholds that identified different sets of ASVs. (Consensus refers to different prevalence thresholds yielding the same sets of ASVs, resulting in the same Bayesian multivariate model).
DOI: 10.25934/pr00007431.0
title: Available IPD datapackage for study 'Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial'

description: In December 2019, the Municipal Health Committee of Wuhan, China, identified an outbreak of viral pneumonia of unknown cause. This new coronavirus was called SARS-CoV-2 and the disease caused by that virus, COVID-19. Recent numbers show that 222,643 infections have been diagnosed with 9115 deaths, worldwide. Currently, there are no approved therapeutic agents available for coronaviruses. In this scenario, the situation of a global public health emergency and evidence about the potential positive effect of chloroquine (CQ) in most coronaviruses, including SARS-CoV-1, and recent data on small trials on SARS-CoV-2, the investigators intend to investigate the efficacy and the safety of CQ diphosphate in the treatment of hospitalized patients with severe acute respiratory syndrome in the scenario of SARS-CoV2. Preliminary in vitro studies and uncontrolled trials with low number of patients of CQ repositioning in the treatment of COVID-19 have been encouraging. The main hypothesis is that CQ diphosphate will reduce mortality in 50% in those with severe acute respiratory syndrome infected by the SARS-COV2. Therefore, the main objective is to assess whether the use of chloroquine diphosphate reduces mortality by 50% in the study population. The primary outcome is mortality in day 28 of follow-up. According to local contingency plan, developed by local government for COVID-19 in the State of Amazonas, the Hospital Pronto-Socorro Delphina Aziz, located in Manaus, is the reference unit for the admission of serious cases of the new virus. The unit currently has 50 ICU beds, with the possibility of expanding to 335 beds, if needed. The hospital also has trained multiprofessional human resources and adequate infrastructure. In total, 440 participants (220 per arm) will receive either high dose chloroquine 600 mg bid regime (4x150 mg tablets, every 12 hours, D1-D10) or low dose chloroquine 450mg bid regime (3x150mg tablets + 1 placebo tablet every 12 hours on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10). Placebo tablets were used to standardize treatment duration and blind research team and patients. All drugs administered orally (or via nasogastric tube in case of orotracheal intubation). Both intervention and placebo drugs will be produced by Farmanguinhos. Clinical and laboratory data during hospitalization will be used to assess efficacy and safety outcomes.
DOI: 10.6084/m9.figshare.18183293
title: Supplemental Table 2

description: All features (ASVs and modules) detected by GLM LASSO runs of sample groups and corresponding plant growth (response) data. Slope estimates, confidence interval bounds, and conditional R\textsuperscript{2} values are given for the subset of features that were selected in Bayesian univariate models. GLM LASSO runs with ASV data show the results from both prevalence thresholds tested.
DOI: 10.6084/m9.figshare.18183185
title: Supplemental Table 1

description: ASVs that varied in differential abundance, as detected by DESeq2, across rhizosphere communities grouped categorically by treatment, block, treatment x time (growth stage or specific day), or treatment x block.
DOI: 10.5281/zenodo.5838722
title: Data for: Competition, prey, and mortalities influence gray wolf group size

description: Data and R code for "Competition, prey, and mortalities influence gray wolf group size" by Sells et al. (2022, Journal of Wildlife Management). The datasets can be used with the included R code to re-create analyses and figures from Sells et al. (2022). The metadata file describes each column in the datasets.
DOI: 10.5281/zenodo.5838721
title: Data for: Competition, prey, and mortalities influence gray wolf group size

description: Data and R code for "Competition, prey, and mortalities influence gray wolf group size" by Sells et al. (2022, Journal of Wildlife Management). The datasets can be used with the included R code to re-create analyses and figures from Sells et al. (2022). The metadata file describes each column in the datasets.
DOI: 10.25934/pr00006720.0
title: Available IPD datapackage for study 'Racial Differences in Vagal Control of Glucose Homeostasis'

description: The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.
DOI: 10.6084/m9.figshare.18185477
title: HMC_variant_list.xlsx

description: List of variants identified by Hamad Medical Corporation to be of interest for inclusion in QChip
DOI: 10.15482/usda.adc/1524468
title: Data from: Amino acid, sugar, phenolic, and terpenoid profiles are capable of distinguishing Citrus tristeza virus infection status in grapefruit, lemon, mandarin, and sweet orange leaves
DOI: 10.5281/zenodo.5834513
title: Data set from example subject

description: This is widefield calcium imaging data from an example subject. Data from two sessions is included: Septermber 20, 2018 and September 24, 2018. Both sessions are from subject mSM63, a triple transgenic Ai95 subject engaged in a detection task in two sensory modalities; GCaMP6 is expressed in all excitatory neurons. Data collection was by Simon Musall, Rirchard Sun and Steven Gluf. Each session contains several files that are used to train the encoding model. The files Vc.mat and rsVC.mat contain the original and downsampled widefield imaging data respectively. This data has also been reduced into spatial components U and temporal components V. The file [mousename]_SpatialDisc_[sessiondate]_Session*.mat contains most of the behavioral information (sensory modality and rate, choice, inter-trial interval, etc.) The Analog.dat files contain data for the piezo sensor (to track hindlimb movements) as well as stimulus onset time. There are also various opts.mat files that contain options used for the widefield imaging. The BehaviorVideo folders contain camera data for the sessions (the data has been SVD'ed for both video and video motion energy). This folder also has a file FilteredPupil.mat which contains data for pupil size, nose, and whisker pads. There is also a bhvOpts.mat file which contains some information on how the camera files were preprocessed. This file structure can be analyzed with rateDisc_RegressModel.mat to generate estimates of neural activity modulation by task variables, instructed, and uninstructed movements during decision-making. <br>
description: {"references": ["https://www.biorxiv.org/content/10.1101/2021.09.27.461599v2"]}
DOI: 10.5281/zenodo.5834512
title: Data set from example subject

description: This is widefield calcium imaging data from an example subject. Data from two sessions is included: Septermber 20, 2018 and September 24, 2018. Both sessions are from subject mSM63, a triple transgenic Ai95 subject engaged in a detection task in two sensory modalities; GCaMP6 is expressed in all excitatory neurons. Data collection was by Simon Musall, Rirchard Sun and Steven Gluf. Each session contains several files that are used to train the encoding model. The files Vc.mat and rsVC.mat contain the original and downsampled widefield imaging data respectively. This data has also been reduced into spatial components U and temporal components V. The file [mousename]_SpatialDisc_[sessiondate]_Session*.mat contains most of the behavioral information (sensory modality and rate, choice, inter-trial interval, etc.) The Analog.dat files contain data for the piezo sensor (to track hindlimb movements) as well as stimulus onset time. There are also various opts.mat files that contain options used for the widefield imaging. The BehaviorVideo folders contain camera data for the sessions (the data has been SVD'ed for both video and video motion energy). This folder also has a file FilteredPupil.mat which contains data for pupil size, nose, and whisker pads. There is also a bhvOpts.mat file which contains some information on how the camera files were preprocessed. This file structure can be analyzed with rateDisc_RegressModel.mat to generate estimates of neural activity modulation by task variables, instructed, and uninstructed movements during decision-making. <br>
description: {"references": ["https://www.biorxiv.org/content/10.1101/2021.09.27.461599v2"]}